Definium Therapeutics DFTX Income Statement (2020-2026)

NASDAQ DFTX
$34.52 -0.12 (-0.35%)
As of: Nov 11, 2026 · 11:18 AM EST
Reported Financials

Definium Therapeutics Quarterly Income Statement

Periods 27 quarters
Latest Sep 2026

Definium Therapeutics reported net income of -$52.21M for the quarter ended Sep 2026. This income statement covers 27 quarters of results from Mar 2020 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Income StatementIncome Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Revenue & cost
Revenue
-0.14M-0.03M0.08M0.36M1.05M1.28M1.31M1.16M0.91M
Operating items
Amortization - Intangibles
Research & DevelopmentR&D
10.88M10.24M9.33M7.77M8.83M12.60M14.78M13.20M11.55M11.71M14.65M17.19M21.76M23.36M29.81M30.98M33.56M41.48M48.67M46.14M
Share-based Compensation (IS)Stock Comp.
Selling, General & AdministrativeSG&A
6.68M8.26M7.62M9.21M5.07M8.26M14.41M8.41M10.66M10.50M9.81M7.60M10.70M8.80M11.09M14.69M14.06M17.74M26.41M26.14M
Other Operating ExpensesOther Opex
0.00M-0.04M
Operating ExpensesOpex
17.56M18.51M16.94M16.98M13.90M20.86M29.18M21.62M22.21M22.20M24.46M24.79M32.46M32.16M40.90M45.67M47.58M59.22M75.08M72.28M
Operating IncomeOp. Inc
-17.56M-18.51M-16.94M-16.98M-13.90M-20.86M-29.18M-21.62M-22.21M-22.20M-24.46M-24.79M-32.46M-32.16M-40.90M-45.67M-47.58M-59.22M-75.08M-72.28M
Non-operating items
Non Operating Interest Expenses
0.08M0.08M0.33M0.44M0.43M0.47M0.73M0.66M0.60M2.34M1.27M1.29M1.25M1.23M1.15M
Gains (Losses) on Sale of Assets & InvestmentsGains on Sales
0.01M0.04M0.20M0.09M-0.26M-0.41M-1.25M
Interest & Investment IncomeInt & Inv Inc
1.36M1.39M1.49M1.34M1.66M3.12M3.51M3.28M2.43M2.77M2.26M3.49M3.46M3.59M10.14M
Other Non Operating IncomeOther Non Op Inc.
-0.43M0.05M-0.09M0.50M9.00M5.19M1.50M3.69M2.97M32.89M18.60M11.11M4.85M8.81M2.23M22.55M5.06M20.05M86.23M21.32M
Non Operating IncomeNon Op. Inc.
-0.43M0.05M-0.01M0.50M9.00M-3.95M-32.20M18.60M11.11M-2.28M8.81M-1.84M-21.60M-2.86M-17.88M-83.91M21.32M
Net income details
EBIT
-17.56M-18.51M-16.94M-16.98M-13.90M-20.86M-29.18M-21.62M-22.21M-22.20M-24.46M-24.79M-32.46M-32.16M-40.90M-45.67M-47.58M-59.22M-75.08M-72.28M
EBT
-17.99M-18.51M-16.96M-16.49M-4.90M-19.58M-27.87M-20.45M-21.30M-20.98M-21.81M-22.01M-29.84M-30.33M-40.47M-44.68M-45.37M-57.01M-72.72M-63.29M
Tax ProvisionsTaxes
-1.16M
Income After Tax
-16.83M-18.51M-16.96M-16.49M-4.90M-19.58M-27.87M-20.45M-21.30M-20.98M-21.81M-22.01M-29.84M-30.33M-40.47M-44.68M-45.37M-57.01M-72.72M-63.29M
Income from Continuing OperationsIncome (Continuing)
-16.83M-18.51M-16.96M-16.49M-4.90M-19.58M-27.87M-20.45M-21.30M-20.98M-21.81M-22.01M-29.84M-30.33M-40.47M-44.68M-45.37M-57.01M-72.72M-63.29M
Consolidated Net IncomeConsol Net Inc.
-16.45M-18.50M-17.10M-16.59M-5.02M-24.80M-29.41M-17.51M-24.30M-53.91M-5.86M-13.70M-34.74M-23.37M-42.74M-67.07M-50.35M-77.36M-159.39M-52.21M
Income towards Parent CompanyParent Net Inc
-16.83M-18.45M-16.96M-16.49M-4.90M-24.82M-29.13M-17.92M-23.86M-54.40M-5.85M-13.68M-34.74M-23.35M-42.74M-67.27M-50.44M-77.10M-158.99M-50.96M
Net Income towards Common StockholdersNet Income
-16.83M-18.45M-16.96M-16.49M-4.90M-24.82M-29.13M-17.92M-23.86M-54.40M-19.30M-22.04M-34.74M-30.35M-42.74M-67.27M-50.44M-77.10M-158.99M-63.31M
Additional items
EPS (Basic)
-0.61-0.66-0.60-0.56-0.16-0.65-0.76-0.45-0.61-1.14-0.27-0.28-0.49-0.36-0.50-0.78-0.56-0.71-1.44-0.47
EPS (Diluted)
-0.61-0.66-0.60-0.56-0.16-0.65-0.76-0.45-0.61-1.14-0.26-0.27-0.49-0.35-0.50-0.78-0.56-0.71-1.44-0.46
Shares Outstanding
27.38M28.15M28.24M29.30M30.86M38.08M38.58M39.72M39.16M47.86M71.91M77.91M70.46M85.07M85.35M85.89M89.33M108.79M110.68M135.94M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
27.38M28.15M28.24M29.30M30.86M38.08M38.58M39.72M39.16M47.86M75.30M80.24M70.46M87.09M85.35M85.89M89.33M108.79M110.68M137.35M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
28.13M28.16M28.45M29.30M30.86M38.29M38.81M40.09M41.10M47.86M72.08M81.59M75.10M75.51M75.80M76.77M98.78M104.04M110.68M136.90M
Interest ExpensesInt Expense
0.08M0.08M0.33M0.44M0.43M0.47M0.73M0.66M0.60M2.34M1.27M1.29M1.25M1.23M1.15M

Definium Therapeutics Income Statement API

Pull Definium Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=DFTX&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY